☆ 4.6 Article

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

FRONTIERS IN ONCOLOGY (2021)

Related references

Note: Only part of the references are listed.

Meeting Abstract Oncology

Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.

Marwan Fakih et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Colon Cancer, Version 2.2021

Al B. Benson et al.

Summary: This section of the NCCN Clinical Practice Guidelines in Oncology focuses on systemic therapy options for metastatic colorectal cancer, with important updates including first-line use of checkpoint inhibitors and expanded recommendations for biomarker testing.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Yun Fan et al.

Summary: The study demonstrated potential antitumor activity of camrelizumab plus apatinib in patients with ED-SCLC who had failed platinum-based chemotherapy, including those who were chemotherapy-sensitive and chemotherapy-resistant. Treatment-related adverse events of grade 3 or higher were reported in a significant proportion of patients, leading to treatment discontinuation in some cases. Further clinical studies are warranted to explore the efficacy of this combination therapy in SCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Oncology

Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1

Hao Song et al.

Summary: Camrelizumab, a humanized anti-PD-1 antibody, has shown significant anti-cancer activity and low incidence of adverse reactions in preclinical and clinical studies on various tumors. Further research is needed to verify its application potential in different types of cancer despite current progress.

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2021)

Add to Collection

Meeting Abstract Oncology

A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.

Xiao-li Wei et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Cell Biology

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

Feng Wang et al.

Summary: This study demonstrates the efficacy of regorafenib plus toripalimab in treating colorectal cancer, as well as the response rates in specific patient populations and the occurrence of treatment-related adverse events. Patients with liver metastases show lower response rates, and those with higher abundance of Fusobacterium have shorter progression-free survival.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Oncology

Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study

Feng-E Jiang et al.

Summary: This study investigated the efficacy and safety of regorafenib or fruquintinib combined with camrelizumab in treating patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer. The combination therapy showed promising efficacy with manageable toxicity, and common adverse events included RCCEP, fatigue, hypertension, hand-foot skin reaction, and thyroid dysfunction.

NEOPLASMA (2021)

Add to Collection

Article Oncology

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).

Alexander Stein et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.

Chunyan Lan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

Jieqiong Liu et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Review Oncology

Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?

Emmanouil Damilakis et al.

CANCERS (2020)

Add to Collection

Article Oncology

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer

Chongkai Wang et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial

Jingde Chen et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Johannes J. M. Kwakman et al.

ONCOLOGY REVIEWS (2020)

Add to Collection

Article Oncology

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study

Jisheng Li et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Michael J. Overman et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Immunology

Immune Responses in the Liver

Paul Kubes et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)

Add to Collection

Article Oncology

LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

A Grothey et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Sabine Tejpar et al.

JAMA ONCOLOGY (2017)

Add to Collection

Review Oncology

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management

B. McLellan et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann et al.

LANCET ONCOLOGY (2014)

Add to Collection

Review Oncology

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

Viswanath Reddy Belum et al.

INVESTIGATIONAL NEW DRUGS (2013)

Add to Collection

Article Oncology

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study

Leonard B. Saltz et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.